Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma

Key Inclusion Criteria: * Men or women over 18 years old * Patients with local, advanced or inoperable or metastatic (MRCC) renal cell carcinoma who are starting first line treatment with Sunitinib 50mg (4/6 regimen) according to the Marketing Authorisation Indication * Patients with histologically or cytologically confirmed renal cancer, clear cell variant or with a clear cell component * Karnofsky performance status ≥ 70% * Adequate organ function: * Absolute neutrophil (N) count ≥ 1 500 / µL * Platelets ≥ 100 000 / µL * Haemoglobin ≥ 10 g/dL * Adjusted serum calcium ≤ 2.6 mmol/L * Creatinine clearance ≥ 30 mL/min (by the MDRD formula) * Total bilirubin ≤ 1.5 x ULN (upper limit of the normal range) * AST ≤ 2.5 x ULN and ALT ≤ 2.5 x ULN OR AST and ALT ≤ 5 x ULN if liver abnormalities due to liver metastases AST = aspartate aminotransferase ALT = alanine aminotransferase Key Exclusion Criteria: * Renal carcinoma with no clear cell component. * Previous systemic treatment for the RCC regardless of type (including targeted therapy, immunotherapy, chemotherapy, hormone or experimental therapy). Previous or concomitant treatment with a bisphosphonate or denosumab is allowed. * Patients whose clinical state and comorbidities are not consistent with administration of Sunitinib at the initial dose of 50mg/day 4 weeks out of 6. * Grade 3 haemorrhage within 4 weeks before starting treatment with Sunitinib (according to the NCI-CTCAE toxicity score version 3.0). * The…